Literature DB >> 26358362

Oncoplastic reduction mammoplasty for breast cancer in women with macromastia: Oncological long-term outcomes.

Mustafa Emiroglu1, Semra Salimoglu2, Cem Karaali2, Ismail Sert2, Osman Gungor3, Fatma Sert4, Cengiz Aydın2.   

Abstract

OBJECTIVE: To evaluate the long-term results of tumorectomy and concomitant bilateral oncoplastic reduction mammoplasty (ORM) for early stage breast cancer patients with macromastia in terms of local disease control and long-term oncological results. PATIENTS AND
METHOD: Data of 82 patients with macromastia undergoing ORM for breast cancer between 1996 and 2011 were retrospectively examined and evaluated with regard to oncological results.
RESULTS: The median age was 50 years. The median follow-up was 121 months (range 28-212 months). The median breast volume was 1402 cm3 and the median weight of excised breast material was 679 g. The median surgical margin was 16 mm. Ten-year local recurrence rate was 8.7%. The 10-year overall survival rate was 82.2% and the disease-free survival rate was 73.2%. Early and late complication rates were 12.2% and 14.6%, respectively.
CONCLUSIONS: From the standpoint of local disease control and long-term observation, ORM can be considered a very safe and acceptable treatment for early stage breast cancer in women with macromastia.
Copyright © 2015. Published by Elsevier Taiwan.

Entities:  

Keywords:  breast cancer; cosmesis; macromastia; oncoplastic breast reduction; satisfaction

Mesh:

Year:  2015        PMID: 26358362     DOI: 10.1016/j.asjsur.2015.07.007

Source DB:  PubMed          Journal:  Asian J Surg        ISSN: 1015-9584            Impact factor:   2.767


  5 in total

1.  National Consensus on Oncoplastic Breast Conserving Surgery in Turkey: Position Paper for the Standardization of Surgical Practice.

Authors:  Mustafa Emiroglu; Cem Karaali; Mehmet B Oztop; Bahadır M Gulluoglu
Journal:  Turk J Surg       Date:  2020-09-28

2.  [Application of three-pedicle reduction mammaplasty in breast cancer patients with moderate or greater breast hypertrophy and/or moderate-to-severe breast ptosis].

Authors:  Yu Feng; Juan Li; Donglin Zhang; Jiao Zhou; Xiangquan Qin; Xiran Liu; Mengxue Qiu; Huanzuo Yang; Zhenggui Du
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2021-12-15

3.  Oncoplastic Level II Surgical Techniques for Breast Cancer Treatment: Long-Term Outcomes.

Authors:  Mehmet Ali Gulcelik; Lutfi Dogan; Niyazi Karaman; Melike Bahcecitapar; Cihangir Ozaslan
Journal:  Breast Care (Basel)       Date:  2021-03-01       Impact factor: 2.860

4.  The Senologic International Society Survey on Ductal Carcinoma In Situ: Present and Future.

Authors:  Carole Mathelin; Massimo Lodi; Khalid Alghamdi; Bolivar Arboleda-Osorio; Eli Avisar; Stanley Anyanwu; Mohcen Boubnider; Mauricio Maghales Costa; Elisabeth Elder; Tony Elonge; Luiz Gebrim; Xishan Hao; Shigeru Imoto; Esther Meka; Michel Mouelle; Alexander Mundinger; Valerijus Ostapenko; Serdar Özbaş; Tolga Özmen; Vahit Özmen; Tadeusz Pienkowski; Gustavo Sarria; Ashraf Selim; Vladimir Semiglazov; Schlomo Schneebaum
Journal:  Eur J Breast Health       Date:  2022-07-01

5.  Outcome reporting in therapeutic mammaplasty: a systematic review.

Authors:  Alice Lee; Richard M Kwasnicki; Hasaan Khan; Yasmin Grant; Abigail Chan; Angela E E Fanshawe; Daniel R Leff
Journal:  BJS Open       Date:  2021-11-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.